Skip to main content
BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
69.71
-4.81 (-6.45%)
At close: Apr 28, 2026, 4:00 PM EDT
70.25
+0.54 (0.77%)
After-hours: Apr 28, 2026, 6:32 PM EDT

BridgeBio Pharma Revenue

In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth. BridgeBio Pharma had revenue of $154.18M in the quarter ending December 31, 2025, with 2,521.18% growth.

Revenue (ttm)
$502.08M
Revenue Growth
+126.26%
P/S Ratio
27.19
Revenue / Employee
$598,422
Employees
839
Market Cap
13.51B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025502.08M280.17M126.26%
Dec 31, 2024221.90M212.60M2,285.27%
Dec 31, 20239.30M-68.35M-88.02%
Dec 31, 202277.65M7.93M11.38%
Dec 31, 202169.72M61.47M745.14%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Incyte 5.36B
Jazz Pharmaceuticals 4.27B
Genmab 3.72B
BioMarin Pharmaceutical 3.22B
Exelixis 2.32B
Moderna 1.94B
Arrowhead Pharmaceuticals 1.09B
Madrigal Pharmaceuticals 958.40M
Revenue Rankings

BBIO News

More News